Testosterone therapy, thrombophilia-hypofibrinolysis, and hospitalization for deep venous thrombosis-pulmonary embolus: an exploratory, hypothesis-generating study.
In our study of 596 men hospitalized in the last 3 years for deep venous thrombosis-pulmonary emboli (DVT-PE), we determined the prevalence of exogenous testosterone (T) use with subsequent development of DVT-PE. Of the 596 men, 110 were now dead, 97 had cancer thought to cause DVT-PE, 250 could not be contacted, leaving 139, of whom 7 had taken T before and at the time of their admissions, 1.2% of the total cohort, a conservative estimate of the prevalence of T-associated DVT-PE. In all, 5 of the 7 DVT-PE events occurred within 3 months of initiation of T, with mean and median intervals between initiation of T and hospitalization with DVT-PE 6.7 and 2 months. Of the 7 men treated with exogenous T, all 5 men who had evaluation of thrombophilia-hypofibrinolysis were found to have previously undiagnosed familial or acquired thrombophilia or hypofibrinolysis, suggesting a thrombotic interaction between exogenous T and thrombophilia-hypofibrinolysis.
1Jewish Hospital Cholesterol Center, Jewish Hospital of Cincinnati, Cincinnati, OH, USA.
Charles J
CJ
Glueck
Caitlin
C
Richardson-Royer
Reiker
R
Schultz
Tim
T
Burger
Dedrick
D
Bowe
Jagjit
J
Padda
Ping
P
Wang
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D011655:Pulmonary Embolism / Q000139:chemically induced*; D013739:Testosterone / Q000008:administration & dosage / Q000009:adverse effects*; D019851:Thrombophilia / Q000139:chemically induced*; D020246:Venous Thrombosis / Q000139:chemically induced*
D013739:Testosterone
blood coagulation factors; clinical epidemiology; clinical thrombophilia; deep venous thrombosis; endocrinology; hypercoagulability